Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715248 | 0.90 | CTSK (0.50) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL29964087 | 0.90 | CTSK (0.50) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL21715243 | 0.88 | CTSK (0.48) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL6123084 | 0.87 | POLB (0.38) | ALDH1A1TSHRTRPM8 | |
| SCHEMBL20211107 | 0.87 | ALDH1A1 (0.57) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL20211106 | 0.87 | ALDH1A1 (0.57) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL21543692 | 0.86 | CTSK (0.52) | CTSKCTSSJAK3BTKCTSL | |
| SCHEMBL20211104 | 0.84 | CTSK (0.54) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL6122352 | 0.84 | CTSK (0.54) | CTSKCTSSALDH1A1TSHRJAK3 | |
| SCHEMBL31277610 | 0.84 | CTSK (0.54) | CTSKCTSSJAK3BTKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | 7 HILLS INTERESTS LLC (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | CTSK 1100/4885CTSS 724/4885ALDH1A1 1970/4885 |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | VCAM1, ITGB1, ITGA1 | CTSK 1887/4885CTSS 1982/4885ALDH1A1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.